Moderna, Inc. (ETR:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 9.45B |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | -3.11B |
| Shares Out | n/a |
| EPS (ttm) | -8.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 715 |
| Average Volume | 552 |
| Open | 24.09 |
| Previous Close | 24.69 |
| Day's Range | 23.68 - 24.23 |
| 52-Week Range | 20.18 - 147.06 |
| Beta | 1.86 |
| RSI | 55.48 |
| Earnings Date | Jul 31, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.
This Is What Whales Are Betting On Moderna
Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ: MRNA) revealed 20 unusual trades. Delving into the details, we found 40% of trad...
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
What you need to know about Moderna’s new COVID vaccine, just approved by the FDA
The shot had previously been approved for everyone 12 and older. Now, there are limits.
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Moderna Stock Is Trading Higher Monday: What's Going On?
Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the ... Full story available on Benzinga.com
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2210922831-bff0c45e5a474d03997ff3bdc2cbc054.jpg)
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More
U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries reached last month.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2208760953-4495e54cc9944edb91ea325b9883574d.jpg)
Moderna Stock Climbs as FDA Approves New COVID-19 Vaccine
Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.
Moderna Stock Is Rising. A New Covid Vaccine Is Coming for Some People.
Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ: MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged...
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.'s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 year...
Stocks making the biggest premarket moves: Cleveland-Cliffs, Nucor, Moderna, Tesla and more
These are the stocks posting the largest moves in the premarket.
Marjorie Taylor Greene slams FDA green lighting of mNEXSPIKE COVID-19 vaccine: 'Not MAHA at all!!!'
Rep. Marjorie Taylor Greene slams FDA green lighting of Moderna's mNEXSPIKE COVID-19 vaccine, describing the move as "Not MAHA at all!!!' in a post on X
Stocks to Watch Monday: Cleveland-Cliffs, Stellantis, Moderna
FDA grants limited approval to new Covid vaccine from Moderna
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical conditi...
Moderna wins FDA nod for next-gen COVID-19 shot
US approves new Moderna Covid jab for over-65s
WASHINGTON - The US Food and Drug Administration has approved Moderna’s next-generation Covid-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the r...
New Covid vaccine approved by US FDA: Here's all about it
The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for adults 65 and older, and individuals aged 12-64 with underlying risk factors...
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regul...
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Trump Administration Cancels $600 Million Contract to Develop Bird Flu Vaccine
The administration cited concerns about mRNA technology; however, Moderna says the vaccine causes a "rapid, potent and durable immune response" to the virus
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
HHS cancels Moderna contract for development of bird flu vaccine for humans
The Department of Health and Human Services announced this week that it had canceled its contract with Moderna to develop a bird flu mRNA vaccine for humans. In a statement, the department wrote that ...